Capreomycin
| DRUG INFORMATION |
| Drug Name |
| Capreomycin |
 |
| Synonyms |
| capreomycin, CHEMBANK921, 11003-38-6, 1500157 |
| Drug Class |
| Second-Line Drugs |
| Year of Introduction |
| 1967 |
| Molecular Target |
| ? |
| Genes Involved in Drug Resistance |
| ? |
| CAS No: |
| 11003-38-6 |
| PHARMACOLOGY |
| Route |
| im |
| Side effects |
| Frequent: nephrotoxicity (20-25%), tubular dysfunction, azotemia, proteinuria. Occasional: ototoxicity (vestibular>auditory); electrolyte abnormalities; pain, induration and sterile abscesses at injection sites. |
| Toxicity |
| Medium |
| Cost |
| High |
| Usual Adult Dosage |
| 15-30mg/kg/day (max: 1 Gm/day) IM or IV qd or 2-3x/week |
| Form |
| vial |
| Brand Name |
| Capastat |
| Manufacturer |
| Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA, Phone: +1-317-276-2000 |
| STRUCTURAL DETAILS |
| Molecular Formula |
| C25H44N14O8 |
| Molecular Weight in g/mol |
| 668.706 |
| Hydrogen Bond Donor Count |
| 14 |
| Hydrogen Bond Acceptor Count |
| 15 |
| Rotatable Bond Count |
| 11 |
| IUPAC Name |
| 3,6-diamino-N-[[15-amino-11-(2-amino-3,4,5,6-tetrahydropyrimidin-4-yl)-8-(carbamoylaminomethylidene)-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide |
| SMILES |
| C1CN=C(NC1C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)NC(=CNC(=O)N)C(=O)N2)CNC(=O)CC(CCCN)N)CO)N)N |
| InChI |
| 1.0RC/C25H44N14O8/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H 3,29,31,38)(H3,30,34,47) |
New Search